Multiple SclerosisNCT00445367
Biobank For MS And Other Demyelinating Diseases
An observational study of Multiple Sclerosis and Transverse Myelitis, run by Accelerated Cure Project for Multiple Sclerosis at 10 sites in United States.
Trial summary
To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica
- How many people
- 3,226 participants
- Where
- 10 sitesUnited States
- Study dates
- May 2006to Oct 2036
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls.
Who may be able to join
- age 18+ able to give informed consent or individuals younger than 18 with parental permission and able to give assent
- willing to provide up to 110 ml (50 ml for < 18 years old) of blood via venipuncture
- experienced at least one CNS demyelinating event characteristic of MS, TM, NMO, ADEM, or ON
Who cannot join
- history of blood borne pathogens
- allogeneic bone marrow transplant
- clinical or radiological evidence of stroke, meningitis, or other well characterized diseases of the nervous system (with the exception of MS, TM, NMO, ADEM, or ON).
- weight less than 37 pounds
Trial locations and contacts
10 sites in 1 country.
10 sites in 1 country
United States10 sites
Shepherd Center
Atlanta, Georgia, 30309
The Rocky Mountain MS Center at Anschutz Medical Campus at UC Denver
Aurora, Colorado, 80045
Johns Hopkins
Baltimore, Maryland, 21287
Beth Israel Deaconess
Boston, Massachusetts, 02215
The Ohio State University
Columbus, Ohio, 43210
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, 76051
Multiple Sclerosis Research Center of New York
New York, New York, 10019
Barrow Neurological Institute
Phoenix, Arizona, 85013
Stanford University
Stanford, California, 94305
University of Massachusetts Medical School
Worcester, Massachusetts, 01605
About this study
Official title: Large-scale, Multi-disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases
To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls. Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.
- Conditions
- Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Optic Neuritis
- Keywords
- Multiple Sclerosis, Clinically Isolated Syndrome, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Optic Neuritis, Repository, Biobank
- Medical subject headings
- Multiple Sclerosis, Myelitis, Transverse, Neuromyelitis Optica, Encephalomyelitis, Acute Disseminated, Optic Neuritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Case | Not described | |
| Control | Not described |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Mar 2007 (estimated)
- Study startMay 2006
- Primary completionOct 2030 (estimated)
- Study completionOct 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Other
- Enrolment
- 3,226 participants (actual)
Sponsor and investigators
- Lead sponsor
- Accelerated Cure Project for Multiple Sclerosis
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Benjamin Greenberg, M.D., M.H.S., Principal investigator, University of Texas
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00445367
- Sponsor's protocol ID
- ACP-001
- Status last verified
- Sep 2025
- First submitted
- 8 Mar 2007
- Last updated
- 2 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Large-scale, Multi-disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases
- ClinicalTrials.gov ID
- NCT00445367
- Acronym / sponsor ID
- ACP-001
- Conditions
- Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Optic Neuritis
- Keywords
- Multiple Sclerosis, Clinically Isolated Syndrome, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Optic Neuritis, Repository, Biobank
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 3,226 participants (actual)
- Lead sponsor
- Accelerated Cure Project for Multiple SclerosisUniversity, hospital or other
- Study start
- May 2006
- Primary completion
- Oct 2030 (estimated)
- Study completion
- Oct 2036 (estimated)
- First posted
- 9 Mar 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls. Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.
Study design
- Observational model
- Case-control
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Case | – | – |
| Control | – | – |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls.
Key inclusion criteria (3 listed)
- age 18+ able to give informed consent or individuals younger than 18 with parental permission and able to give assent
- willing to provide up to 110 ml (50 ml for < 18 years old) of blood via venipuncture
- experienced at least one CNS demyelinating event characteristic of MS, TM, NMO, ADEM, or ON
Key exclusion criteria (4 listed)
- history of blood borne pathogens
- allogeneic bone marrow transplant
- clinical or radiological evidence of stroke, meningitis, or other well characterized diseases of the nervous system (with the exception of MS, TM, NMO, ADEM, or ON).
- weight less than 37 pounds
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2025.
- Accelerated Cure Project MS Repository OverviewLink provided by the sponsor.
Related trials for Multiple Sclerosis
RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Relapsing Multiple Sclerosis
Active, not recruitingObservational study
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Study of Skin Tumors in Tuberous Sclerosis
Tuberous Sclerosis
Recruiting
The Effects of Synchronous and Asynchronous Pilates Training Based on Telerehabilitation on Core Stabilization, Balance, Cognitive Functions, and Quality of Life in Individuals With Multiple Sclerosis: A Single-Blind Randomized Controlled Trial
Multiple Sclerosis
RecruitingObservational study
Care in Multiple Sclerosis (MS)
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Benjamin Greenberg, M.D., M.H.S. principal investigator
University of Texas
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Sclerosis and Transverse Myelitis, run by Accelerated Cure Project for Multiple Sclerosis at 10 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2025.